United Therapeutics Corporation (UTHR) – What Are Analysts Thinking About This Stock?

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $642.69.

Several research firms have commented on UTHR. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Bank of America lowered their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Jefferies Financial Group reissued a “buy” rating and set a $728.00 price target on shares of United Therapeutics in a research report on Wednesday. Finally, Royal Bank Of Canada raised their price target on United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th.

Insider Activity

In other news, EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $544.30, for a total value of $4,517,690.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,587,119.60. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $539.99, for a total value of $5,129,905.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $175,195,975.57. This represents a 2.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 392,028 shares of company stock valued at $202,884,996. Company insiders own 8.60% of the company’s stock.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Toth Financial Advisory Corp grew its stake in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after buying an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics in the second quarter valued at about $30,000. Caitlin John LLC purchased a new stake in United Therapeutics in the second quarter valued at about $37,000. International Assets Investment Management LLC raised its stake in United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. acquired a new stake in United Therapeutics in the second quarter worth about $81,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

UTHR stock opened at $533.12 on Friday. The company has a market capitalization of $22.87 billion, a PE ratio of 19.07, a P/E/G ratio of 3.81 and a beta of 0.49. The firm’s 50-day moving average is $513.64 and its 200 day moving average is $540.40. United Therapeutics has a 12 month low of $409.07 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the business earned $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. Sell-side analysts forecast that United Therapeutics will post 26.40 EPS for the current fiscal year.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
• Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement
• Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares.
• Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels.
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing
• Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.